Federal Register: October 28, 2009 (Volume 74, Number 207)
DOCID: fr28oc09-106 FR Doc E9-26003
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
NOTICE: NOTICES
DOCID: fr28oc09-106
SUBJECT CATEGORY:
Manufacturer of Controlled Substances; Notice of Application
DOCUMENT SUMMARY:
Pursuant to Sec. 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on June 18, 2009, Archimica, Inc., 2460 W. Bennett Street, Springfield, Missouri 658071229, made application by letter to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of Tapentadol (9780), a basic class of controlled substance listed in schedule II.
The company plans to manufacture the listed controlled substance in bulk for distribution to its customers.
Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).
Any such written comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than December 28, 2009.
Dated: October 21, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.
[FR Doc. E926003 Filed 102709; 8:45 am]
BILLING CODE 441009P
SUMMARY:
Manufacturer of Controlled Substances; Applications
DOCUMENT BODY 2:
Pursuant to Sec. 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on June 18, 2009, Archimica, Inc., 2460 W. Bennett Street, Springfield, Missouri 658071229, made application by letter to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of Tapentadol (9780), a basic class of controlled substance listed in schedule II.
The company plans to manufacture the listed controlled substance in bulk for distribution to its customers.
Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).
Any such written comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than December 28, 2009.
Dated: October 21, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.
[FR Doc. E926003 Filed 102709; 8:45 am]
BILLING CODE 441009P